In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease

Archives of General Psychiatry

Volumn 56, Issue 2, 1999, Pages 185-192

  Pfefferbaum, Adolf ^a,b   Adalsteinsson, Elfar ^b   Spielman, Daniel ^b   Sullivan, Edith V ^b   Lim, Kelvin O ^c  

^a SRI INTERNATIONAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; GRAY MATTER; HUMAN; IN VIVO STUDY; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; AGE FACTORS; AGED; ALZHEIMER DISEASE; CEREBRAL CORTEX; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHOCREATINE;

EID: 0033001444     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.2.185     Document Type: Article

References (83)

1. Tanabe JL, Amend D, Schuff N, DiSclafani V, Ezekiel F, Norman D, Fein G, Weiner MW. Tissue segmentation of the brain in Alzheimer disease. AJNR Am J Neuroradiol. 1997;18:115-123.
2. Rusinek H, De Leon MJ, George AE, Stylopoulos LA, Chandra R, Smith G, Rand T, Mourino M, Kowalski H. Alzheimer disease: measuring loss of cerebral gray matter with MR imaging. Radiology. 1991;178:109-114.
3. Fama R, Sullivan EV, Shear PK, Marsh L, Yesavage JA, Tinklenberg JR, Lim KO, Pfefferbaum A. Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease. Arch Neurol. 1997;54:719-728.
4. Jernigan TL, Salmon DP, Butters N, Shults CW, Hesselink JR. Specificity of brain-structural changes in Alzheimer's, Huntington's, and Parkinson's diseases. J Clin Exp Neuropsychol. 1990;12:410.
5. De Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet. 1989;2:672-673.
6. Cahn DA, Sullivan EV, Shear PK, Marsh L, Fama R, Lim KO, Yesavage JA. Tinklenberg JR, Pfetferbaum A. Structural MRI correlates of recognition memory in Alzheimer's disease. J Int Neuropsychol Soc. 1998;4:106-114.
7. Soininen HS, Partanen K, Pitkanen A, Vainio P, Hanninen T, Hallikainen M, Koivisto K, Riekkinen PJ. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology. 1994;44:1660-1668.
8. Seab JP, Jagust WJ, Wong STS, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements ot hippocampal atrophy in Alzheimer's disease. Magn Reson Med. 1988;8:200-208.
9. Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett. 1993;153:131-135.
10. Kemper TL. Neuroanatomical and neuropathological changes during aging and dementia. In: Albert, ML, Knoefel, JE, eds. Clinical Neurology of Aging. New York, NY: Oxford University Press; 1994.
11. Brun A, Englund E. The pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology. 1981;5:549-564.
12. Brun A, Gustafson L, Englund E. Subcortical pathology of Alzheimer's disease. Alzheimer Dis Assoc Disord. 1990;51:73-77.
13. Braak H, Braak E. Alzheimer's disease affects limbic nuclei ot the thalamus. Acta Neuropathol (Berl). 1991;81:261-268.
14. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
15. Hof PR. Morphology and neurochemical characteristics of the vulnerable neurons in brain aging and Alzheimer's disease. Eur Neurol. 1997;37:71-81.
16. Arnold SE, Hyman BT, Van Hoesen G. Neuropathological changes of the temporal pole in Alzheimer's disease and Pick's disease. Arch Neurol 1994;51:145-150.
17. Mufson EJ. Lack of neocortical nerve cell loss in Alzheimer's disease: reality or methodological artifact. Neurobiol Aging. 1994;15:361-362.
18. Braak H, Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging. 1994;15:355-356.
19. Regeur L, Jensen GB, Pakkenberg H, Evans SM, Pakkenberg B. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol Aging. 1994;15:347-352.
20. Swaab DF, Hofman MA, Lucassen PJ, Salehi A, Uylings HBM. Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease. Neurobiol Aging. 1994; 15:369-371.
21. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging study of changes in Drain morphology from infancy to late adulthood. Arch Neurol. 1994;51:874-887.
22. Raz N, Gunning FM, Head D, Dupuis JH, McQuain J, Briggs SD, Loken WJ, Thornton AE, Acker JD. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. Cereb Cortex. 1997;7:268-282.
23. Blatter DD, Bigler ED, Gale SD, Johnson SC, Anderson C, Burnett BM, Parker N, Kurth S, Horn S. Quantitative volumetric analysis of brain MRI: normative database spanning 5 decades of life. Am J Neuroradiol. 1995;16:241-245.
24. Jernigan TL, Archibald SL, Berhow MT, Sowell ER, Faster DS, Hesselink JR. Cerebral structure on MRI, I: localization of age-related changes. Biol Psychiatry. 1991;29:55-67.
25. Guttmann CRG, Jolesz FA, Kikinis R, Killiany RJ, Moss MB, Sandor T, Albert MS. White matter changes with normal aging. Neurology. 1998;50:972-978.
26. Tang Y, Nyengaard JR, Pakkenberg B, Gundersen HJG. Age-induced white-matter changes in the human brain: a stereological investigation. Neurobiol Aging. 1997;18:609-615.
27. Flood DG, Coleman PD. Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease. In: Storm-Mathisen J, Zimmer J, Otterson OP, eds. Progress in Brain Research: Understanding the Brain Through the Hippocampus. Amsterdam, the Netherlands: Elsevier Science Publishers; 1990;83: 435-443.
28. Flood DG. Region-specific stability of dendritic extent in normal human aging and regression in Alzheimer's disease, II: subiculum. Brain Res. 1991;540:83-95.
29. Flood DG. Critical issues in the analysis of dendritic extent in aging humans, primates, and rodents. Neurobiol Aging. 1993;14:649-654.
30. Tallan HH. Studies on the distribution of N-acetyl-L-aspartate acid in brain. J Biol Chem. 1956;224:41-45.
31. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-f NTR spectroscopy. Radiology. 1997;203:829-836.
32. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease: a proton MR spectroscopic imaging and MRI study. Neurology. 1997;49:1513-1521.
33. Klunk WE, Panchalingam K, Moossy J, McClure RJ, Pettegrew JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer s disease brain: a preliminary proton nuclear magnetic resonance study. Neurology. 1992;42:1578-1585.
34. Lim KO, Spielman DM. Estimating NAA in cortical gray matter with applications for measuring changes due to aging. Magn Reson Med. 1997;37:372-377.
35. Charles HC, Lazeyras F, Krishnan KRR, Boyko OB, Patterson LJ, Doraiswamy PM, McDonald WM. Proton spectroscopy of human brain: effects of age and sex. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:995-1004.
36. Fukuzako H, Hashiguchi T, Sakamoto Y, Okamura H, Doi W, Takenouchi K, Takigawa M. Metabolite changes with age measured by proton magnetic resonance spectroscopy in normal subjects. Psychiatry Clin Neurosci. 1997;51:261-263.
37. Christiansen P, Toft P, Larsson HBW, Stubgaard M, Henriksen O. The concentration of N-acetyl aspartate, creatine+phosphocreatine, and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging. 1993;11:799-806.
38. Pfefferbaum A, Sullivan E, Adalsteinsson A, Spielman D, Lim KO. In vivo quantification of N-acetyl aspartate, creatine and choline from large volumes of gray and white matter on magnetic resonance spectroscopic imaging: application to normal aging. Magn Reson Med. 1999;41:276-294.
39. Chang L, Ernst T, Poland RE, Jenden DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci. 1996;58:2049-2056.
40. Meyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, Fein G, Weiner MW. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol. 1994; 36:40-47.
41. Soher BJ, van Zijl PCM, Duyn JH, Barker PB. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med. 1996;35:356-363.
42. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II: metabolite concentrations. J Magn Reson. 1993;102:9-19.
43. Saunders DE, Howe FA, van den Boogaart A, Griffith JR, Brown MM. Aging of the human adult brain: in vivo quantification of metabolic content with proton magnetic resonance spectroscopy [abstract]. Proc Soc Magn Reson. 1995;3: 1804.
44. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev. 1997;97:9-14.
45. Frederick BD, Satlin A, Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry. 1997;42:147-150.
46. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular-and Alzheimer-type dementia. Arch Neurol. 1996;53:678-680.
47. Tedeschi G, Bertolino A, Lundbom N, Bonavita S, Patronas NJ, Duyn JH, Metman LV, Chase TN. Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology. 1996;47:696-704.
48. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn J, Alger J. Di Chiro G. Increased choline signal coinciding with malignant degeneration ot cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997;87:516-524.
49. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ. In vivo H-1 MRS choline: correlation with in vitro chemistry histology. Life Sci. 1996;58:1929-1935.
50. Moyher SE, Nelson SJ, Wald LL, Henry RG, Kurhanewicz J, Vigneron DB. High-spatial resolution MRS and segmented MRI to study NAA in cortical gray matter and white matter of the human brain [abstract]. Proc Soc Magn Reson. 1995;1:332.
51. Narayana PA, Fotedar LK, Jackson EF, Bohan TP, Butler IJ, Wolinsky JS. Regional in vivo proton magnetic resonance spectroscopy of brain. J Magn Reson. 1989;83:44-52.
52. Wang Y, Li S-J. Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy. Magn Reson Med. 1998;39:28-33.
53. Doyle TJ, Beddell BJ, Narayana PA. Relative concentration of proton MR visible neurochemicals in gray and white matter in human brain. Magn Reson Med. 1995; 33:755-759.
54. Kwo-On-Yuen PF, Newmark RD, Budinger TF, Kaye JA, Ball MJ, Jagust WJ. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res. 1994;667:167-174.
55. Petroff OA, Spencer DD, Alger JR, Pitchard JW. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology. 1989;39:1197-1202.
56. Petroff OAC, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate and GABA content of the epileptic human brain. Magn Reson Imaging. 1995;13:1197-1211.
57. Tedeschi G, Bertolino A, Righini A, Campbell G, Raman R, Duyn JH, Moonen CTW. Alger JR, Di Chiro G. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology. 1995;45:1384-1391.
58. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. 1998;39:53-60.
59. 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med. 1996;36:21-29.
60. Knufman NMJ, Berkelbach, van der Sprenkel JW, Tulleken CAF. N-Acetyl-aspartate differences between gray and white matter as observed by proton spectroscopic imaging in normal subjects [abstract]. Proc Soc Magn Reson. 1992: 1905.
61. McKhann G, Drachman D, Folstein M, Katzman R. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;37:939-944.
62. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097-1105.
63. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
64. Warrington E. Recognition Memory Test Manual. Windsor, England: Nelson Publishing Co; 1984.
65. Huff FJ, Collins C, Corkin S, Rosen TJ. Equivalent forms of the Boston Naming Test. J Clin Exp Neuropsychol. 1986;8:556-562.
66. Adalsteinsson E, Irarrazabal P, Spielman DM, Macovski A. Three-dimensional spectroscopic imaging with time-varying gradients. Magn Reson Med. 1995;33: 461-466.
67. Spielman D, Adalsteinsson E, Lim KO. Quantitative analysis of improved homogeneity using linear versus higher order shims for CSF of the brain [abstract]. In: Abstracts of the Firth Scientific Meeting of the International Society for Magnetic Resonance in Medicine: April 12-18, 1997: Vancouver, British Columbia.
68. Webb P, Macovski A. Rapid, fully-automatic, arbitrary volume, in-vivo shimming. Magn Reson Med. 1991;20:113-122.
69. Gudbjartsson H, Patz S. The Rician distibution of noisy MRI data. Magn Reson Med. 1995;34:910-914.
70. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW. Regional gray and white matter metabolite differences in subjects with AD. with subcortical ischemic vascular dementia, and elderly controls with H-1 magnetic resonance spectroscopic imaging. Arch Neurol. 1996;53:167-174.
71. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer's disease. Magn Reson Med. 1994; 32:110-115.
72. Mohanakrishnan P, Fowler AH, Vonsattel JP, Jolles PR, Husain MM, Liem P, Myers L, Komoroski RA. Regional metabolic alterations in Alzheimer's disease: an in vitro H-1 NMR study of the hippocampus and cerebellum. J Gerontol A Biol Sci Med Sci. 1997;52:6111-6117.
73. Jaarsma D, Veenma van der Duin L, Korf J. N-acetylaspartate and N-acetyl-aspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. J Neurol Sci. 1994;127:230-233.
74. Mohanakrishnan P, Fowler AH, Vonsattel JP, Husain MM, Jolles PR, Liem P, Komoroski RA. An in vitro H-1 nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains. Exp Brain Res. 1995;102:503-510.
75. Pettegrew J, Moossy J, Withers G, McKeag D, Panchalinpam K. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neuml. 1988;47:235-248.
76. Brown G, Levine S, Gorell J, Pettegrew J, Gdowski J, Bueri J, Helpern J, Welch K. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology. 1989;39:1423-1427.
77. Bottomley PA, Cousins JP, Pendrey DL, Wagle WA, Hardy CJ, Eames FA, McCaffrey RJ, Thompson DA. Alzheimer dementia: quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy. Radiology. 1992;183:695-699.
78. Murphy DGM, Bottomley PA, Salerno JA, DeCarli C, Mentis MJ, Grady CL, Teichberg D, Giacometti KR, Rosenberg JM, Hardy CJ, Schapiro MB, Rapoport SI, Alger JR, Horwitz B. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry. 1993;50:341-349.
79. Gonzalez RG, Guimaraes AR, Moore GJ, Crawley A, Cupples LA, Growdon JH. Quantitative in vivo P-31 magnetic resonance spectroscopy of Alzheimer disease. Alzheimer Dis Assoc Dis. 1996;10:46-52.
80. Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative H-1 and P-31 MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging. 1996;17:349-357.
81. Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging. 1995;16:973-975.
82. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology. 1993;187:219-227.
83. Smith CD, Pettigrew LC, Avison MJ, Kirsch JE, Tinkhtman AJ, Schmitt FA, Wermeling DP, Wekstein DR, Markesberry WR. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol. 1995;38:194-201.